Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Has results × rrCLL × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1916 Neoplasms 1379 Carcinoma, Non-Small-Cell Lung 1307 Prostatic Neoplasms 1048 Multiple Myeloma 841 Leukemia, Myeloid, Acute 748 Neoplasm Metastasis 685 Colorectal Neoplasms 666 Melanoma 662 Lung Neoplasms 659 Lymphoma 650 Leukemia 588 Lymphoma, Non-Hodgkin 583 Leukemia, Lymphocytic, Chronic, B-Cell 528 Ovarian Neoplasms 514 Pancreatic Neoplasms 485 Precursor Cell Lymphoblastic Leukemia-Lymphoma 468 Recurrence 462 Myelodysplastic Syndromes 416 Lymphoma, Follicular 404 Head and Neck Neoplasms 394 Carcinoma, Renal Cell 373 Glioblastoma 370 Lymphoma, Large B-Cell, Diffuse 368 Brain Neoplasms 367 Hodgkin Disease 348 Carcinoma, Hepatocellular 322 Squamous Cell Carcinoma of Head and Neck 316 Lymphoma, Mantle-Cell 301 Sarcoma 277

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡